FGF21 is beneficial in NASH [49], and muscle-derived FGF21 could wield hepatic effects, given that in our CD-HFD model the expression in the muscle, but not the liver, increased in response to exercise (Figure 12). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.